J
Juan Diego Morillas
Researcher at Hospital Clínico San Carlos
Publications - 41
Citations - 2480
Juan Diego Morillas is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Colorectal cancer & Colonoscopy. The author has an hindex of 22, co-authored 41 publications receiving 2296 citations. Previous affiliations of Juan Diego Morillas include Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening
Enrique Quintero,Antoni Castells,Luis Bujanda,Joaquín Cubiella,Dolores Salas,Angel Lanas,Montserrat Andreu,Fernando Carballo,Juan Diego Morillas,Cristina Hernández,Rodrigo Jover,Isabel Montalvo,Juan Arenas,Eva Laredo,Vicent Hernandez,Felipe Iglesias,Estela Cid,Raquel Zubizarreta,Teresa Sala,Marta Ponce,Mercedes Andrés,Gloria Teruel,Antonio Peris,María-Pilar Roncales,Mónica Polo-Tomás,Xavier Bessa,Olga Ferrer-Armengou,Jaume Grau,Anna Serradesanferm,Akiko Ono,José Cruzado,Francisco Pérez-Riquelme,Inmaculada Alonso-Abreu,Mariola de la Vega-Prieto,Juana María Reyes-Melián,Guillermo Cacho,José Díaz-Tasende,Alberto Herreros-de-Tejada,Carmen Poves,Cecilio Santander,Andrés González-Navarro +40 more
TL;DR: Subjects in the FIT group were more likely to participate in screening than were those in the colonoscopy group, and more adenomas were identified in thecolorectal cancer group.
Journal ArticleDOI
Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome.
J.A. Solis-Herruzo,A. Duran,V. Favela,Gregorio Castellano,J.L. Madrid,M. T. Muñoz-Yagüe,Juan Diego Morillas,J. Estenoz +7 more
TL;DR: It is concluded that sympathetic block might improve renal function in cirrhotics with hepatorenal syndrome, particularly those with more impaired GFR.
Journal ArticleDOI
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
Rodrigo Jover,Pedro Zapater,Antoni Castells,Xavier Llor,Montserrat Andreu,Joaquín Cubiella,Virginia Piñol,Rosa M. Xicola,Luis Bujanda,Josep Maria Reñe,Juan Clofent,Xavier Bessa,Juan Diego Morillas,David Nicolás-Pérez,Artemio Payá,Cristina Alenda +15 more
TL;DR: Benefit from 5-FU adjuvant chemotherapy depends on the MMR status of tumours in patients with colorectal cancer but this benefit from chemotherapy cannot be extended to patients with MMR deficient tumours.
Journal ArticleDOI
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Rodrigo Jover,Pedro Zapater,Antoni Castells,Xavier Llor,Xavier Llor,Montserrat Andreu,Joaquín Cubiella,Francesc Balaguer,Laura Sempere,Rosa M. Xicola,Rosa M. Xicola,Luis Bujanda,Josep Maria Reñe,Juan Clofent,Xavier Bessa,Juan Diego Morillas,David Nicolás-Pérez,Elisenda Pons,Artemio Payá,Cristina Alenda +19 more
TL;DR: In a cohort of colorectal cancer patients, those with MMR-deficient tumours seem not to benefit from 5-FU-based chemotherapy.
Journal ArticleDOI
5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer
Rodrigo Jover,Thuy Nguyen,Lucía Pérez–Carbonell,Pedro Zapater,Artemio Payá,Cristina Alenda,Estefanía Rojas,Joaquín Cubiella,Francesc Balaguer,Francesc Balaguer,Juan Diego Morillas,Juan Clofent,Luis Bujanda,Josep Maria Reñe,Xavier Bessa,Rosa M. Xicola,David Nicolás Pérez,Antoni Castells,Montserrat Andreu,Xavier Llor,C. Richard Boland,Ajay Goel +21 more
TL;DR: Patients with CIMP-positive colorectal tumors do not benefit from 5-FU-based adjuvant chemotherapy and are not an independent predictor of outcome.